eligibility_summary
Include: Adults (≥18) with confirmed cFL, R/R after 1–3 prior systemic anti‑CD20 lines, needing therapy, ECOG ≤2, measurable disease, adequate counts and renal/hepatic function, can swallow, contraception/negative pregnancy. Exclude: >3 lines, RT‑only early stage, prior BTKi or CD20xCD3, transformed FL, allo‑HSCT, bleeding/stroke, CNS lymphoma, recent therapy or CAR‑T, significant CV disease, active infection (HBV/HCV on tx, HIV), other cancer <3y, pregnancy, severe pulmonary/GI issues, live vaccine, hypersensitivity, autoimmune incl AIHA/ITP.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 single-arm trial in relapsed/refractory follicular lymphoma testing mosunetuzumab + zanubrutinib. Mosunetuzumab: subcutaneous CD20×CD3 T-cell–engaging bispecific monoclonal antibody, mechanism: bridges CD20 on malignant B cells and CD3 on T cells to redirect cytotoxic T cells and deplete B cells (CRS manageable with tocilizumab). Zanubrutinib: oral covalent small-molecule Brutons tyrosine kinase (BTK) inhibitor, mechanism: blocks B-cell receptor signaling (BTK→PLCγ2/NF-κB/MAPK), reducing B-cell activation, proliferation, and survival. Targets: CD20+ FL B cells, effector CD3+ T cells, and the BCR/BTK pathway. Regimen: zanubrutinib pre-phase, M+Z induction, zanubrutinib maintenance.